Clinical trials: Advanced Tumor
Hepatocellular Carcinoma
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
This open-label, multicenter phase II study was designed to evaluate the safety and efficacy of JS207 alone or in combination with JS007 as first-line treatment in subjects with advanced HCC.
- Trial name
- NCT06954467
- Testing
- JS207, JS007
- Where
- 12 sites in China
- Volunteers
- 72 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Solid Tumor, Androgen Receptor Gene Overexpression
Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma
This study's purpose is to facilitate and expedite the clinical testing of SEVI-D in a population with advanced GBM that are androgen receptor (AR) positive.
- Trial name
- START (NCT03600467)
- Testing
- SEVI-D (Seviteronel in combination with dexamthasone)
- Where
- Australia
- Volunteers
- 4 people
- Sponsor
- St Vincent's Hospital, Sydney
HER2 Overexpression, Advanced Stage Breast Cancer
A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer
The study is an open, prospective study to collect data on the efficacy and safety of T-DXd (DS8201) in Chinese patients with HER2 overexpressing and HER2 underexpressing advanced breast cancer in actual clinical practice in…
- Conditions
- HER2 Overexpression, Advanced Stage Breast Cancer, Low Expression of HER2
- Trial name
- NCT07035353
- Testing
- T-DXd (DS8201) 5.4 mg/kg, IVD, 1 cycle every 21 days.
- Volunteers
- 200 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer
Hydroxychloroquine and Gefitinib to Treat Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common cause of cancer mortality in men and women in Singapore.Chemotherapy and biologically targeted agents can extend survival only modestly for these patients; therefore…
- Trial name
- NCT00809237
- Testing
- Gefitinib, Hydroxychloroquine
- Where
- Singapore
- Volunteers
- 71 people
- Sponsor
- National University Hospital, Singapore
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Rectal Cancer
Hyperthermia With Chemoradiotherapy in Rectal Cancer
The goal of this clinical trial is to evaluate the efficacy of deep regional hyperthermia in the context of radiochemotherapy followed by consolidation chemotherapy in locally advanced rectal cancer.
- Trial name
- ARO 2024-13 (NCT06831981)
- Testing
- Hyperthermia, Radiotherapy, Chemotherapy with 5-fluorouracil
- Where
- 2 sites in Germany
- Volunteers
- 264 people
- Sponsor
- University Hospital Tuebingen
Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.
- Trial name
- NCT06424665
- Testing
- FZ-AD005
- Where
- 3 sites in China
- Volunteers
- 162 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Lung Cancer
Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC
Fruquintinib administered at 4 mg once daily in cycle 1 and 5 mg once daily in followed cycles (3 weeks on and 1 week off, 4 weeks as 1 cycle) was well tolerated and demonstrated encouraging preliminary clinical antitumor…
- Trial name
- NCT03684967
- Testing
- Fruquintinib
- Where
- China
- Sponsor
- Hutchison Medipharma Limited
Biliary Tract Cancer
A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with locally advanced or metastatic HER2 overexpressed biliary tract cancer who have failed first-line chemotherapy.
- Trial name
- NCT04329429
- Testing
- RC48-ADC
- Where
- 16 sites in China
- Volunteers
- 57 people
- Sponsor
- RemeGen Co., Ltd.
Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
This phase Ib trial studies the side effects and best dose of IRX-2 when given together with cyclophosphamide and nivolumab in treating patients with liver cancer that has come back or spread to other parts of the body and does…
- Conditions
- Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT03655002
- Testing
- Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Neoplasms
Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan
The purpose of this clinical study is to establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (or dose range as appropriate) of BMS-907351 (XL184) when administered orally on a once daily schedule in subjects…
- Trial name
- NCT01018745
- Testing
- BMS-907351 (XL184)
- Where
- Japan
- Volunteers
- 3 people
- Sponsor
- Bristol-Myers Squibb
HEAD AND NECK CANCER
Accelerated Fractionation Radiotherapy (AFRT) Versus Concurrent Chemoradiotherapy (Crt) In Locally Advanced Head And Neck Squamous Cell Carcinoma
The aim of this trial is to compare the accelerated fractionation radiotherapy and concurrent chemo-radiotherapy in locally advanced head and neck squamous cell carcinoma patients in terms of loco-regional control, toxicities and…
- Trial name
- NCT01291095
- Testing
- CISPLATIN, EXTERNAL BEAM RADIOTHERAPY
- Where
- India
- Volunteers
- 80 people
- Sponsor
- All India Institute of Medical Sciences
Breast Cancer
SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases
The aim of this project is to evaluate whether the sequence of Trastuzumab，pyrotinib and Nab-Paclitaxel in first line followed by SHR-A1811 in second line is superior to the sequence of SHR-A1811 in first line followed by…
- Trial name
- NCT06975475
- Testing
- SHR-A1811,tratuzumab,pyrotinib,Nab-Paclitaxel
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced Breast Cancer
Study of DM5167 in Patients With Advanced Solid Tumors
DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety.
- Trial name
- NCT07101601
- Testing
- DM5167
- Where
- 4 sites in South Korea
- Volunteers
- 58 people
- Sponsor
- DIGMBIO
Polycystic Ovary Syndrome, Vitamin D Deficiency
Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS
The purpose of this study is to investigate the mechanism that explain the beneficial clinical effect of vitamin D treatment in women with PCOS.
- Trial name
- NCT03644212
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Maimonides Medical Center
Advanced or Metastatic Breast Cancer
Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer
This is a single arm, multicentric phase II study of milademetan plus fulvestrant in patients with ER+, HER2- ABC harboring GATA3 mutation(s) in the tumor and/or in ctDNA who have progressed on or after prior treatments including…
- Trial name
- DEMETER (NCT05932667)
- Testing
- Milademetan, Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)
- Where
- 6 sites in France
- Volunteers
- 1 people
- Sponsor
- Institut Curie
Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer
Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors
This study evaluates the safety, tolerability, preliminary efficacy and pharmacokinetics of Simmitecan in patients with advanced solid tumors and Simmitecan, 5-fluorouracil and Leucovorin Calcium,thalidomide in patients with…
- Trial name
- NCT02870036
- Testing
- Simmitecan, 5-fluorouracil and Leucovorin Calcium, Thalidomide
- Where
- 9 sites in China
- Volunteers
- 243 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
Hepatocellular carcinoma (HCC) with main trunk portal vein tumor thrombus (PVTT) has poor prognosis. The main lethiferous factor is the upper gastrointestinal hemorrhage by PVTT-related portal hypertension, then the second is the…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy
- Trial name
- NCT06622031
- Testing
- Transjugular intrahepatic portosystemic shunt, Lenvatinib, PD-1 inhibitor
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo in patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT00108953
- Testing
- Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
- Where
- 28 sites in United States, Argentina and 4 more
- Volunteers
- 96 people
- Sponsor
- Bayer
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.